Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele

Middleton, Peter G., Mall, Marcus A., Dřevínek, Pavel, Lands, Larry C., McKone, Edward F., Polineni, Deepika, Ramsey, Bonnie W., Taylor-Cousar, Jennifer L. +13 more·2019·New England Journal of Medicine
DOI 10.1056/nejmoa1908639

Cited by (2,225)

Items 601–700 of 2,225

  1. Adenine base editing with engineered virus-like particles rescues the CFTR mutation G542X in patient-derived intestinal organoids
    Lucia Nicosia, Iwona Maria Pranke, Roberta V. Latorre, Joss B. Murray, Lisa Lonetti, Kader Cavusoglu-Doran, Elise Dréano, James P. Costello, Michael Adam Carroll, Paola Melotti et al. · 2025 · iScience
  2. Trends in Cystic Fibrosis–Related Diabetes Epidemiology Between 2003 and 2018 From the U.S. Cystic Fibrosis Foundation Patient Registry
    C Köhler, Tim Vigers, Laura Pyle, Kristen Miller, Edith T. Zemanick, Antoinette Moran, Scott D. Sagel, Christine L. Chan · 2025 · Diabetes Care
  3. Fecal microbiota changes in people with cystic fibrosis after 6 months of elexacaftor/tezacaftor/ivacaftor: Findings from the promise study
    Jennifer Duong, Hillary S. Hayden, Adrian J. Verster, Christopher E. Pope, Carson J. Miller, Kelsi M. Penewit, Stephen J. Salipante, Steven Mark Rowe, George Marty Solomon, David P. Nichols et al. · 2025 · Journal of Cystic Fibrosis
  4. Mechanisms of Lung Cancer Development in Cystic Fibrosis Patients: The Role of Inflammation, Oxidative Stress, and Lung Microbiome Dysbiosis
    Raffaella Pagliaro, Filippo Scialò, Angela Schiattarella, Roberta Cianci, Susan F. M. Campbell, Fabio Perrotta, Andrea Bianco, Giuseppe Castaldo · 2025 · Biomolecules
  5. Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey
    Nazan Çobanoğlu, Uğur Özçelik, Erkan Çakır, Tuğba Şişmanlar Eyüboğlu, Sevgi Pekcan, Güzin Cinel, Ebru Yalçın, Nural Ki̇per, Nagehan Emiralioğlu, Velat Şen et al. · 2020 · Pediatric Pulmonology
  6. Challenging the paradigm: moving from umbrella labels to treatable traits in airway disease
    Andrew Bush, Ian Douglas Pavord · 2021 · Breathe
  7. Congenital etiologies of exocrine pancreatic insufficiency
    Isabelle Scheers, Silvia Berardis · 2022 · Frontiers in Pediatrics
  8. Dynamic Perfluorinated Gas MRI Shows Improved Lung Ventilation in People with Cystic Fibrosis after Elexacaftor/Tezacaftor/Ivacaftor: An Observational Study
    Jennifer L. Goralski, Sang Hun Chung, Agathe Ceppe, Margret Z. Powell, Muthu Kumar Sakthivel, Brian Handly, Yueh Z. Lee, Scott H. Donaldson · 2022 · Journal of Clinical Medicine
  9. Current and Future Therapeutic Approaches of Exocrine Pancreatic Insufficiency in Children with Cystic Fibrosis in the Era of Personalized Medicine
    Mirela Elena Ritivoiu, Cristina Manuela Drăgoi, Dumitru Bucur Matei, Iustina Violeta Stan, Alina Crenguţa Nicolae, Mihai Craiu, Ion-Bogdan Dumitrescu, Alina Angelica Ciolpan · 2023 · Pharmaceutics
  10. Use of cystic fibrosis inhaled medication before and after elexacaftor/tezacaftor/ivacaftor initiation
    Κaterina Manika, Filia Diamantea, Άννα Τσάκωνα, Alexandros Kakolyris, Athina Sopiadou, Serafeim‐Chrysovalantis Kotoulas, Maria Sionidou, Sirmo-Stiliani Kirvasili, Marija Hadji-Mitrova, Eleni Papadaki et al. · 2023 · Journal of Cystic Fibrosis
  11. Cystic fibrosis
    Isabelle Fajac, Pierre‐Régis Burgel · 2023 · La Presse Médicale
  12. Effect of 18 months elexacaftor-tezacaftor-ivacaftor on body mass index and glycemic control in adults with cystic fibrosis
    Valerie Taelman, Dimitri Declercq, Stéphanie Van Biervliet, Yannick Vande Weygaerde, Bruno Lapauw, Eva Van Braeckel · 2023 · Clinical Nutrition ESPEN
  13. Cystic fibrosis airway inflammation enables elexacaftor/tezacaftor/ivacaftor-mediated rescue of N1303KCFTRmutation
    Martina Gentzsch, Brooke Baker, Deborah M. Cholon, Charissa W. Kam, Cameron J. McKinzie, Katherine A. Despotes, Susan E. Boyles, Nancy L. Quinney, Charles R. Esther, Carla M. P. Ribeiro · 2023 · ERJ Open Research
  14. A randomised trial of oral prednisone for cystic fibrosis pulmonary exacerbation treatment
    Valerie J. Waters, Michelle Shaw, Lucy Perrem, Bradley S. Quon, Elizabeth D. Tullis, Melinda P. Solomon, Jonathan H. Rayment, Annick Lavoie, Sze Man Tse, Patrick Daigneault et al. · 2024 · European Respiratory Journal
  15. Potentiation of BKCa channels by cystic fibrosis transmembrane conductance regulator correctors VX-445 and VX-121
    Aaron Kolski‐Andreaco, Stefanie N. Taiclet, Michael M. Myerburg, John Sembrat, Robert J. Bridges, Adam C. Straub, Zachary P. Wills, Michael Bruce Butterworth, Daniel C. Devor · 2024 · Journal of Clinical Investigation
  16. Is Obesity a Problem in New Cystic Fibrosis Treatments?
    Marta Solís García, Marta María García Clemente, Claudia Janeth Madrid-Carbajal, Adrián Peláez, Rosa Mar Gómez Punter, José María Eiros Bachiller, Rosa María Girón · 2024 · Nutrients
  17. Rewriting CFTR to cure cystic fibrosis
    Giulia Maule, Marjolein M. Ensinck, Mattijs Bulcaen, Marianne Sylvia Carlon · 2021 · Progress in molecular biology and translational science
  18. Sex differences in treatment patterns in cystic fibrosis pulmonary exacerbations
    Kristina Montemayor, Kevin J. Psoter, Noah Lechtzin, Sara W. Carson, Christian A. Merlo, Rebecca Dezube, Kristin A. Riekert, Sarah Allgood, Alexandra H. Toporek, Mark T. Jennings et al. · 2021 · Journal of Cystic Fibrosis
  19. Cysteamine Inhibits Glycine Utilisation and Disrupts Virulence in Pseudomonas aeruginosa
    Douglas J. Fraser-Pitt, Stephen K. Dolan, David Toledo-Aparicio, Jessica G. Hunt, Daniel W. Smith, Niamh Lacy-Roberts, Piumi Sara Nupe Hewage, Teodora N. Stoyanova, Erin D. T. Manson, Kevin McLean et al. · 2021 · Frontiers in Cellular and Infection Microbiology
  20. The effect of the cystic fibrosis care center on outcomes after lung transplantation for cystic fibrosis
    Errol L. Bush, Aravind Krishnan, Alexis P. Chidi, Eric P. Nolley, Sean T. Agbor-Enoh, Natalie E. West, Erin Tallarico, Jonathan B. Orens, Jinny Suk Ha, Pali D. Shah et al. · 2021 · The Journal of Heart and Lung Transplantation
  21. Rescue of Mutant CFTR Trafficking Defect by the Investigational Compound MCG1516A
    Miquéias Lopes‐Pacheco, Mafalda Bacalhau, Sofia S. Ramalho, Iris A. L. Silva, Filipa C. Ferreira, Graeme W. Carlile, David Y. Thomas, Carlos Miguel Farinha, John W. Hanrahan, Margarida Duarte Amaral · 2022 · Cells
  22. Elexacaftor, tezacaftor and ivacaftor: a case of severe rash and approach to desensitisation
    Ann Cheng, Olivia Baker, Uta G Hill · 2022 · BMJ Case Reports
  23. Losartan ameliorates TGF-β1–induced CFTR dysfunction and improves correction by cystic fibrosis modulator therapies
    Michael D. Kim, Charles D. Bengtson, Makoto Yoshida, Asef J. Niloy, John S. Dennis, Nathalie Baumlin, Matthias A. Salathe · 2022 · Journal of Clinical Investigation
  24. Genetic evidence supports the development of SLC26A9 targeting therapies for the treatment of lung disease
    Jiafen Gong, Gengming He, Cheng Wang, Claire Bartlett, Naim Panjwani, Scott Mastromatteo, Lin Fan, Katherine Keenan, Julie Avolio, Anat Halevy et al. · 2022 · npj Genomic Medicine
  25. Lubiprostone is a Non-Selective Activator of cAMP-Gated Ion Channels and Chloride Channel Protein 2 (Clc-2) Has a Minor Role in its Prosecretory Effect in Intestinal Epithelial Cells
    Apurva A. Oak, Tifany Chu, Pattareeya Yottasan, Parth D. Chhetri, Jie Zhu, J. Du Bois, Onur Çil · 2022 · Molecular Pharmacology
  26. Structure basis of CFTR folding, function and pharmacology
    Tzyh‐Chang Hwang, Ineke Braakman, Peter van der Sluijs, Isabelle Callebaut · 2022 · Journal of Cystic Fibrosis
  27. The Impact of Highly Effective Cystic Fibrosis Transmembrane Conductance Regulator Modulators on the Health of Female Subjects With Cystic Fibrosis
    Jennifer L. Taylor‐Cousar, Michal Shteinberg, Malena Cohen‐Cymberknoh, Raksha Jain · 2023 · Clinical Therapeutics
  28. Potential systemic effects of acquired CFTR dysfunction in COPD
    Marc Miravitlles, Gerard J. Criner, Marcus Alexander Mall, Steven Mark Rowe, Claus Franz Vogelmeier, Bettina Hederer, Matthias Schoenberger, Pablo Altman · 2023 · Respiratory Medicine
  29. Elexacaftor/tezacaftor/ivacaftor in children aged ≥6 years with cystic fibrosis heterozygous for F508del and a minimal function mutation: results from a 96-week open-label extension study
    Marcus Alexander Mall, Claire Elizabeth Wainwright, Julian P. Legg, Mark A. Chilvers, Silvia Gärtner, Anna‐Maria Dittrich, Florian Stehling, Sarah C. Conner, Sebastian Grant, Nina E. Suresh et al. · 2025 · European Respiratory Journal
  30. ANO1: central role and clinical significance in non-neoplastic and neoplastic diseases
    Yanghao Hu, Yifei Zhang, Jiali He, Huihuang Rao, Duomi Zhang, Zhisen Shen, Chongchang Zhou · 2025 · Frontiers in Immunology
  31. Advances in cystic fibrosis: CFTR modulator triple combinations
    Pierre‐Régis Burgel, Marcus Alexander Mall · 2025 · European Respiratory Journal
  32. Utilization of the Healthy Eating Index in Cystic Fibrosis
    Rosara Bass, Alyssa M. Tindall, Saba Sheikh · 2022 · Nutrients
  33. Identification of novel F508del-CFTR traffic correctors among triazole derivatives
    Mafalda Bacalhau, Filipa C. Ferreira, Arthur Henrique Pezzo Kmit, Felipe Rodrigues de Souza, Verônica Diniz da Silva, André Silva Pimentel, Margarida Duarte Amaral, Camilla Djenne Buarque, Miquéias Lopes‐Pacheco · 2022 · European Journal of Pharmacology
  34. Thermodynamic and kinetic approaches for drug discovery to target protein misfolding and aggregation
    Michele Vendruscolo · 2023 · Expert Opinion on Drug Discovery
  35. Hyperbilirubinemia and Gilbert's syndrome in Cystic Fibrosis patients treated with elexacaftor/tezacaftor/ivacaftor
    Vito Terlizzi, Silviana Timpano, M. Salvi, Antonella Tosco, Alice Castaldo, Cristina Fevola, G. Leonetti, Pamela Vitullo, Angela Ornella Sepe, Raffaele Badolato et al. · 2023 · Journal of Cystic Fibrosis
  36. Effects of elexacaftor/tezacaftor/ivacaftor on liver fibrosis markers in adults with cystic fibrosis
    Daniel H. Tewkesbury, Jennifer A. Scott, Peter James Barry, Rowland J. Bright-Thomas, Karen Piper Hanley, Varinder Singh Athwal, Andrew M. Jones · 2023 · Journal of Cystic Fibrosis
  37. Qualitative and quantitative evaluation of computed tomography changes in adults with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor: a retrospective observational study
    Sabine Dettmer, Oliver Weinheimer, Annette Sauer‐Heilborn, Oliver Lammers, Mark Oliver Wielpütz, Jan Fuge, Tobias Welte, Frank K. Wacker, Felix C. Ringshausen · 2023 · Frontiers in Pharmacology
  38. Impact of Elexacaftor/Tezacaftor/Ivacaftor on Healthcare Resource Utilization and Associated Costs Among People With Cystic Fibrosis in the US: A Retrospective Claims Analysis
    Michael S. Schechter, Natalia Sabater Anaya, Gerry Oster, Derek A. Weycker, Hongsheng Wu, Emilio Arteaga‐Solis, Sukirti Bagal, Lisa J. McGarry, Kate Van Brunt, Jessica Morlando Geiger · 2023 · Pulmonary Therapy
  39. Changes in vitamins and trace elements after initiation of highly effective CFTR modulator therapy in children and adults with cystic fibrosis – a real-life insight
    Dorit Fabricius, Tina Knieling, Noelle Zurmühl, Leandra Makedon, Joachim Freihorst, Hanna Schmidt, Sebastian F. N. Bode · 2024 · Molecular and Cellular Pediatrics
  40. Update on the Role of Chest Imaging in Cystic Fibrosis
    Scott M. Bugenhagen, Jacob C. E. Grant, Daniel Rosenbluth, Sanjeev Bhalla · 2024 · Radiographics
  41. Real-world impact of Elexacaftor-Tezacaftor-Ivacaftor treatment in young people with Cystic Fibrosis: A longitudinal study
    Gary James Connett, Maguire S, T. Larcombe, Niamh Scanlan, Supriya Suresh Shinde, T. Muthukumarana, Amanda Bevan, Ruth H. Keogh, Julian P. Legg · 2024 · Respiratory Medicine
  42. Discovery and Development of CFTR Modulators for the Treatment of Cystic Fibrosis
    Xueqing Wang, Chris Tse, Ashvani K. Singh · 2025 · Journal of Medicinal Chemistry
  43. Novel bacterial topoisomerase inhibitors derived from isomannide
    Antony A. Okumu, Yanran Lu, Sheri Dellos-Nolan, Jonathan L. Papa, Bryan J. Koci, Nicholas T. Cockroft, Judith C. Gallucci, Daniel J. Wozniak, Jack C. Yalowich, Mark J. Mitton‐Fry · 2020 · European Journal of Medicinal Chemistry
  44. The Changing Face of Cystic Fibrosis and Its Implications for Screening
    Lutz Naehrlich · 2020 · International Journal of Neonatal Screening
  45. Characterization of the mechanism of action of RDR01752, a novel corrector of F508del-CFTR
    Miquéias Lopes‐Pacheco, Iris A. L. Silva, Mark J. Turner, Graeme W. Carlile, Elvira Sondo, David Y. Thomas, Nicoletta Pedemonte, John W. Hanrahan, Margarida Duarte Amaral · 2020 · Biochemical Pharmacology
  46. How to determine the mechanism of action of CFTR modulator compounds: A gateway to theranostics
    Margarida Duarte Amaral · 2020 · European Journal of Medicinal Chemistry
  47. Evaluation of the Effectiveness of In‐line Immobilized Lipase Cartridge in Enterally Fed Patients With Cystic Fibrosis
    Meghana Sathe, Dhiren R. Patel, Archie Stone, Eric R. First · 2020 · Journal of Pediatric Gastroenterology and Nutrition
  48. Computed Tomographic Changes in Patients with Cystic Fibrosis Treated by Combination Therapy with Lumacaftor and Ivacaftor
    François Arnaud, Nathalie Stremler-Le Bel, Martine Reynaud‐Gaubert, Julien Mancini, Jean‐Yves Gaubert, G. Gorincour · 2021 · Journal of Clinical Medicine
  49. Non‐invasive prenatal diagnosis of single gene disorders by paternal mutation exclusion: 3 years of clinical experience
    Mathilde Pacault, Camille Verebi, Maureen Lopez, Nicolas Vaucouleur, Lucie Orhant, Nathalie Deburgrave, France Leturcq, Dominique Vidaud, Emmanuelle Girodon, Thierry Bienvenu et al. · 2022 · BJOG An International Journal of Obstetrics & Gynaecology
  50. The Effect of Elexacaftor/Tezacaftor/Ivacaftor on Hospitalizations and Intravenous Antibiotic Use
    Eric Walter, Jennifer L Bass · 2022 · The Permanente Journal
  51. Insights gained in the pathology of lung disease through single‐cell transcriptomics
    Gianni Carraro, Barry R. Stripp · 2022 · The Journal of Pathology
  52. Targeting of Glycosaminoglycans in Genetic and Inflammatory Airway Disease
    Robin Caird, Michael Williamson, Azeez Yusuf, Debananda Gogoi, Michelle Casey, Noel Gerard McElvaney, Emer P. Reeves · 2022 · International Journal of Molecular Sciences
  53. A survey assessing the impact of COVID‐19 and elexacaftor/tezacaftor/ifavacaftor on both physical and mental health in adults with cystic fibrosis
    Colleen M. Sakon, Hilary Vogt, Cynthia D. Brown, Emma M. Tillman · 2022 · Pediatric Pulmonology
  54. Production of CFTR-ΔF508 Rabbits
    Dongshan Yang, Xiubin Liang, Brooke D. Pallas, Mark James Hoenerhoff, Zhuoying Ren, Renzhi Han, Jifeng Zhang, Y. Eugene Chen, Jian‐Ping Jin, Fei Sun et al. · 2021 · Frontiers in Genetics
  55. The role of CFTR in the eye, and the effect of early highly effective modulator treatment for cystic fibrosis on eye health
    Elena K. Schneider‐Futschik, Yimin Zhu, Danni Li, Mark D. Habgood, Bao N. Nguyen, Ines Pankonien, Margarida Duarte Amaral, Laura Elizabeth Downie, Holly Rose Chinnery · 2024 · Progress in Retinal and Eye Research
  56. New drugs in cystic fibrosis: what has changed in the last decade?
    Juliana Roda, Catarina Silva, Iris A. L. Silva, Carla Maia, Susana Almeida, Ricardo Ferreira, Guiomar Oliveira · 2022 · Therapeutic Advances in Chronic Disease
  57. Acute pancreatitis in pancreatic-insufficient cystic fibrosis patients treated with CFTR modulators
    Ido Sadras, Malena Cohen‐Cymberknoh, Eitan Kerem, Benjamin Z. Koplewitz, Natalia Simanovsky, Michael A. Wilschanski, Liron Birimberg‐Schwartz, Oded Breuer · 2023 · Journal of Cystic Fibrosis
  58. A grumbling concern: A survey of gastrointestinal symptoms in cystic fibrosis in the modulator era
    Rebecca J Calthorpe, N. Goodchild, Vigilius Gleetus, Vinishaa Premakumar, Bu Hayee, Zoe C Elliott, Bethinn Evans, Nicola Jane Rowbotham, S.B. Carr, Helen Louise Barr et al. · 2023 · NIHR Open Research
  59. Dry Powder Inhalation for Lung Delivery in Cystic Fibrosis
    Xiaoxuan Han, Danni Li, Felisa Reyes‐Ortega, Elena K. Schneider‐Futschik · 2023 · Pharmaceutics
  60. Proliferative activity of antigen-specific CD154+ T cells against bacterial and fungal respiratory pathogens in cystic fibrosis decreases after initiation of highly effective CFTR modulator therapy
    Patience Ndidi Eschenhagen, Petra Bächer, Claudia Grehn, Jochen Georg Mainz, Alexander Scheffold, C. Schwarz · 2023 · Frontiers in Pharmacology
  61. TGF-β1 Inhibition of ACE2 Mediated by miRNA Uncovers Novel Mechanism of SARS-CoV-2 Pathogenesis
    Ewelina D. Hejenkowska, Nilay Mitash, J. Donovan, Anvita Chandra, Carol A. Bertrand, Chiara De Santi, Catherine M. Greene, Fangping Mu, Agnieszka Swiatecka‐Urban · 2023 · Journal of Innate Immunity
  62. The gut-lung axis in the CFTR modulator era
    Florian Lussac‐Sorton, Éléna Charpentier, Sébastien Imbert, Maxime Lefranc, S. Bui, Michael John Fayon, Patrick Berger, Raphaël Enaud, Laurence Delhaès · 2023 · Frontiers in Cellular and Infection Microbiology
  63. Aetiology of Significant Liver Test Abnormalities in a Single-Centre Cohort of People with Cystic Fibrosis Exposed to Elexacaftor/Tezacaftor/Ivacaftor, Utilizing the Updated RUCAM
    Daniel H. Tewkesbury, Andrew M. Jones, Rowland J. Bright-Thomas, Alyn L. Cratchley, Karen Piper Hanley, Judith I. Wyatt, Varinder Singh Athwal, Peter James Barry · 2023 · Drugs
  64. Real world study on elexacaftor‐tezacaftor‐ivacaftor impact on cholesterol levels in adults with cystic fibrosis
    Kevin P. Lonabaugh, G. Li, R. List, Reyna Huang, Amber James, Andrew Julio Barros, Lindsay Somerville, Dana P. Albon · 2023 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
  65. Perceived burden of respiratory physiotherapy in people with cystic fibrosis taking elexacaftor–tezacaftor–ivacaftor combination: a 1-year observational study
    Chiara Blardone, Simone Gambazza, Alessandra Mariani, Rachele Galgani, Anna Brivio, R. Nobili, Carmela Rizza, Anna Luisa Tutino, Andrea Gramegna, Valeria Daccò et al. · 2024 · Therapeutic Advances in Respiratory Disease
  66. Predicting weight gain in patients with cystic fibrosis on triple combination modulator
    Kelly L. Stewart, Rhonda D. Szczesniak, Theodore G. Liou · 2024 · Pediatric Pulmonology
  67. 1-BENZYLSPIRO[PIPERIDINE-4,1′-PYRIDO[3,4-b]indole] ‘co-potentiators’ for minimal function CFTR mutants
    Jung‐Ho Son, Puay‐Wah Phuan, Jie S. Zhu, Soren M. Lipman, Amy Cheung, Ka Yi Tsui, Dean Joseph Tantillo, Alan S. Verkman, Peter M. Haggie, Mark J. Kurth · 2020 · European Journal of Medicinal Chemistry
  68. Current and novel therapeutic strategies for the management of cystic fibrosis
    Douweh Leyla Gbian, Abdelwahab Omri · 2021 · Expert Opinion on Drug Delivery
  69. The effectiveness and value of novel treatments for cystic fibrosis
    Jeffrey A. Tice, Karen M. Kuntz, Kael Wherry, Matt Seidner, David M. Rind, Steven D. Pearson · 2021 · Journal of Managed Care & Specialty Pharmacy
  70. SLC26A9 SNP rs7512462 is not associated with lung disease severity or lung function response to ivacaftor in cystic fibrosis patients with G551D-CFTR
    Alice C. Eastman, Rhonda G. Pace, Hong Dang, Melis A. Aksit, Briana Vecchio-Pagán, Anh-Thu N. Lam, Wanda K. O’Neal, Scott M. Blackman, Michael R. Knowles, Garry R. Cutting · 2021 · Journal of Cystic Fibrosis
  71. Novel reaction to new cystic fibrosis medication Trikafta
    Julian Stashower, Patrick C. Carr, Virginia Miller, Barrett J. Zlotoff · 2021 · Clinical Case Reports
  72. Systematic profiling of temperature- and retinal-sensitive rhodopsin variants by deep mutational scanning
    Andrew G. McKee, Charles P. Kuntz, Joseph T. Ortega, Hope Woods, Victoria Most, Francis J. Roushar, Jens Meiler, Beata Jastrzębska, Jonathan P. Schlebach · 2021 · Journal of Biological Chemistry
  73. At‐home compounding preparation of slow desensitization of elexacaftor/tezacaftor/ivacaftor for delayed hypersensitivity rash
    Corinne A. Muirhead, Deborah Verzasconi, Shyam R. Joshi · 2022 · Pediatric Pulmonology
  74. Animal models of cystic fibrosis in the era of highly effective modulator therapies
    Barbara R. Grubb, Alessandra Livraghi-Butrico · 2022 · Current Opinion in Pharmacology
  75. Super resolution microscopy analysis reveals increased Orai1 activity in asthma and cystic fibrosis lungs
    Alexandra S. Goriounova, Rodney C. Gilmore, Joe A. Wrennall, Robert Tarran · 2022 · Journal of Cystic Fibrosis
  76. Advances in the Cystic Fibrosis Drug Development Pipeline
    Christine Tanaka Esposito, Martin Kämper, Jessica Trentacoste, Susan Galvin, Halie Pfister, Janice Wang · 2023 · Life
  77. Impact of highly effective modulator therapy on chronic rhinosinusitis and health status: 2-year follow-up
    Daniel M. Beswick, Aastha Khatiwada, Jessa E. Miller, Stephen M. Humphries, Alexandra W. M. Wilson, Eszter K. Vladar, David A. Lynch, Jennifer L. Taylor‐Cousar · 2023 · Journal of Cystic Fibrosis
  78. Use of elexacaftor+tezacaftor+ivacaftor in individuals with cystic fibrosis and at least one F508del allele: a systematic review and meta-analysis
    Luiz Vicente Ribeiro Ferreira da Silva Filho, Rodrigo Abensur Athanazio, Carolina Rodrigues Tonon, Juliana Carvalho Ferreira, Suzana Érico Tanni · 2023 · Jornal Brasileiro de Pneumologia
  79. Cystic fibrosis – Ten promising therapeutic approaches in the current era of care
    Ranjani Somayaji, Dave P Nichols, Scott Cameron Bell · 2020 · Expert Opinion on Investigational Drugs
  80. Immunoglobulin A Mucosal Immunity and Altered Respiratory Epithelium in Cystic Fibrosis
    Sophie T. Gohy, Alexandra Moeremans, Charles Pilette, Amandine M. Collin · 2021 · Cells
  81. LONGITUDE: An observational study of the long-term effectiveness of elexacaftor/tezacaftor/ivacaftor in people aged ≥12 years with cystic fibrosis using data from the United Kingdom Cystic Fibrosis Registry - 2-year analysis
    Gabriela Vega-Hernandez, Gordon MacGregor, Andrew Wilfin, Francis Adams, C. Haugh, Carl A. Baxter, Heike Wöhling, Sarah L. Clarke, Susan C. Charman, S.B. Carr · 2025 · Journal of Cystic Fibrosis
  82. Elexacaftor/Tezacaftor/Ivacaftor Effect on Bone Density and Body Composition: A Retrospective Analysis
    Susanne Ursula Trost, Tasma Harindhanavudhi, Qi Wang, Anvitha Reddy Ankireddypalli, Azmi Simrah, Sreekant Avula, Amir A. Moheet · 2025 · Pediatric Pulmonology
  83. Impact of pharmacy services on time to elexacaftor-tezacaftor-ivacaftor initiation
    Lauren Roder, Michelle Simonsen, Lindsey Fitzpatrick, Jianghua He, Jennifer Loucks · 2022 · Journal of Managed Care & Specialty Pharmacy
  84. Endocrine Complications of Cystic Fibrosis
    Andrea True Kelly, Brynn E. Marks, Michael S. Stalvey · 2022 · Clinics in Chest Medicine
  85. Cardiopulmonary Exercise Testing Provides Prognostic Information in Advanced Cystic Fibrosis Lung Disease
    Thomas Radtke, Don S. Urquhart, Julia Braun, Peter James Barry, Ian Waller, N. Petch, Meir Mei‐Zahav, Mordechai Reuven Kramer, T. Hua-Huy, Anh Tuan Dinh‐Xuan et al. · 2023 · Annals of the American Thoracic Society
  86. CFTR is required for zinc-mediated antibacterial defense in human macrophages
    Kaustav Das Gupta, James E. B. Curson, Abdullah A. Tarique, Ronan Kapétanovic, Mark A. Schembri, Emmanuelle Fantino, Peter David Sly, Matthew J. Sweet · 2024 · Proceedings of the National Academy of Sciences
  87. Design and synthesis of fluorine aromatic scaffolds containing drugs approved by the US FDA from 2002 to 2022
    Pengfei Xu, Lijun Zhu, Desheng Zhang, Zilong Li, Raoling Ge, Qiang Tian · 2024 · Results in Chemistry
  88. Elexacaftor/Tezacaftor/Ivacaftor use in Pediatric Cystic Fibrosis Patients with Advanced Liver Disease
    Hannah E Protich, Jean Pappas Molleston, Molly A. Bozic, Rebecca S. Pettit · 2024 · Journal of Cystic Fibrosis
  89. Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with Cystic Fibrosis following liver transplantation: A systematic review
    Ilaria Testa, Giuseppe Indolfi, Rossa E. Brugha, Henkjan J. Verkade, Vito Terlizzi · 2024 · Journal of Cystic Fibrosis
  90. Considerations for the use of inhaled antibiotics for Pseudomonas aeruginosa in people with cystic fibrosis receiving CFTR modulator therapy
    Pierre‐Régis Burgel, Manfred Ballmann, Pavel Dřevı́nek, Harry G.M. Heijerman, Andreas Jung, Jochen Georg Mainz, Daniel Gavin Peckham, Barry J. Plant, C. Schwarz, Giovanni Taccetti et al. · 2024 · BMJ Open Respiratory Research
  91. Unmet challenges in cystic fibrosis treatment with modulators
    Federica Corrao, Mairead Kelly, Isabelle Sermet‐Gaudelus, Michaëla Semeraro · 2024 · Expert Review of Respiratory Medicine
  92. Safety and tolerability of bronchoscopic and nebulised administration of bacteriophage
    Jagdev Singh, Stephanie A. Lynch, Jonathan R. Iredell, Hiran C. Selvadurai · 2024 · Virus Research
  93. Nutritional status in the era of highly effective CFTR modulators
    Rosara Bass, Jessica A. Alvarez · 2024 · Pediatric Pulmonology
  94. Allergic Bronchopulmonary Aspergillosis (ABPA) in the Era of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators
    Paulami Chatterjee, Carson Tyler Moss, Sarah Omar, Ekroop Dhillon, Carlos Hernandez Borges, Alan C. Tang, David A. Stevens, Joe L. Hsu · 2024 · Journal of Fungi
  95. Lung Clearance Index Improves in People with Cystic Fibrosis not Achieving a Clinical Important Difference in Forced Expiratory Volume in One Second After Elexacaftor/Tezacaftor/Ivacaftor Therapy
    Valeria Daccò, Andrea Gramegna, Chiara Rosazza, Alessandra Mariani, Arianna Biffi, Chiara Lanfranchi, Laura Zazzeron, Federica Bellante, Francesco Blasi, Gianfranco Alicandro · 2024 · Lung
  96. Effect of elexacaftor-tezacaftor-ivacaftor on liver transient elastography, fibrosis indices and blood tests in children with cystic fibrosis
    Vito Terlizzi, Cristina Fevola, Martina Cecchetti, Alberto Terminiello, Franco Curci, Elisa Bartolini, Chiara Rubino, Mariangela Stinco, Simona Carrera, Paolo Bonomi et al. · 2025 · Journal of Cystic Fibrosis
  97. Proteomics profiling of inflammatory responses to elexacaftor/tezacaftor/ivacaftor in cystic fibrosis
    Hazel Ozuna, Dinesh Bojja, Santiago Partida‐Sánchez, Luanne Hall‐Stoodley, Amal O. Amer, Rodney Deon Britt, Shahid Ijaz Sheikh, David A. Frank, Weiyuan Wang, Bum‐Yong Kang et al. · 2025 · Frontiers in Immunology
  98. Cutting-Edge Advances in Cystic Fibrosis: From Gene Therapy to Personalized Medicine and Holistic Management
    Giuseppe Fabio Parisi, Vito Terlizzi, Sara Manti, Maria Rosaria Papale, Giulia Pecora, Santiago Presti, Monica Tosto, Salvatore Leonardi · 2025 · Genes
  99. Reported Adverse Events in Patients with CF Receiving Treatment with Elexacaftor/Tezacaftor/Ivacaftor: 5 Years Observational Study
    Francesca Lucca, Ilaria Meneghelli, Gloria Tridello, Francesca Buniotto, Giulia Cucchetto, Sonia Volpi, Emily Pintani, Valentino Bezzerri, Marco Cipolli · 2025 · Journal of Clinical Medicine
  100. Therapeutic peptides for the treatment of cystic fibrosis: Challenges and perspectives
    Valentina Sala, Sophie Cnudde, Alessandra Murabito, Alberto Massarotti, Emilio Hirsch, Alessandra Ghigo · 2021 · European Journal of Medicinal Chemistry